You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动|中国生物制药涨近4%南下资金持续净买入大行唱多
格隆汇 07-15 11:05
格隆汇7月15日丨中国生物制药(01177.HK)涨近4%,报8.85港元,成交3.58亿港元,总市值1114亿港元。据格隆汇APP数据显示,自5月份以来,港股通南下资金持续加仓中国生物制药股票,累计持仓从3%增持目前的4.64%。截止到上周五,南下资金已经连续7个交易日净买入中国生物制药。里昂上周发表报告指,中生制药公布其重磅药品安罗替尼获国家药监局颁发药品注册批件,批准新增适应症“软组织肉瘤”,集团在过去一个月亦获得另外四种仿制药的生产许可。此外,集团旗下药品Alprostadil (Kaishi)亦被列入内地近期公布的全国重点监控目录。该行相信,Alprostadil (Kaishi) 对集团的影响甚少,因该药仅贡献集团去年收入的3.6%,今年则料占2.8%。考虑安罗替尼新增适应症对收入的贡献,里昂上调对中生制药的股份目标价,由9.18港元升至10.56港元,评级维持“买入”。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account